Institut de Génétique Moléculaire de Montpellier (IGMM) - UMR5535


On this website

In the directory

IGMM is supported by

Home page > Industrial Partnerships > Splicos


The Splicos company ( was created in 2008 on the basis of the work of the Tazi group on alternative RNA splicing and the identification of a number of pharmacological inhibitors of this process, with the help of an investor (Truffle Capital) exploiting contractually discoveries made at CNRS. This was followed in 2009 by the creation of a collaborative CNRS/Splicos laboratory (Splicos Therapeutics; hosted at IGMM. Its aim is to identify leads that may interfere with splicing in various pathological situations. Part of the collaborative work between IGMM and Splicos has gained support by OSEO-ISI grant from Bpifrance (the French National Agency for Innovation). Splicos has recently merged with 3 other companies to form the Abivax company (, whose main aim is to commercialize novel antivirals and therapeutics vaccines.

Institut de Génétique Moléculaire de Montpellier
CNRS-UMR 5535 - 1919, Route de Mende - 34293 Montpellier  Cedex 5
(+33) 04 34 35 96 01